T-cell chauvinists versus antibody advocates - Can't we all just get along?

Journal of Clinical Oncology

Volumn 22, Issue 22, 2004, Pages 4446-4448

  Chapman, Paul B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CD20 ANTIGEN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; GANGLIOSIDE GD2; GANGLIOSIDE GD3; GANGLIOSIDE GM2; MONOCLONAL ANTIBODY R24; RITUXIMAB; TRASTUZUMAB; TYROSINASE RELATED PROTEIN 1; VASCULOTROPIN; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANTIGEN SPECIFICITY; B CELL LYMPHOMA; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CELLULAR IMMUNITY; COLON CANCER; CYTOTOXICITY; DNA POLYMORPHISM; EDITORIAL; HUMAN; IMMUNIZATION; LUNG METASTASIS; MELANOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; NOTE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES;

EID: 16544373338     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.06.939     Document Type: Editorial

References (17)

1. Houghton AN, Mintzer D, Cordon-Cardo C, et al: Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A 82:1242-1246, 1985
2. Nasi M, Meyers M, Livingston P, et al: Anti-melanoma effects of R24, a monoclonal antibody against GD3. Melanoma Res 7:S155-S162, 1997 (suppl 2)
3. King DM, Albertini MR, Schalen H, et al: A phase I clinical trial of the immunocytokine EMD 273063 (hu. 14.19-IL2) in melanoma patients. J Clin Oncol 22:4463-4473, 2004
4. Cheung N, Lazarus H, Miraldi F, et al: Ganglioside GD2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 5:1430-1440, 1987
5. Saleh MN, Khazaeli MB, Wheeler RH, et al: Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum Antibodies Hybridomas 3:19-23, 1992
6. Murray JL, Kleinerman ES, Jia SF, et al: Phase 1a/1b trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. J Immunother Emphasis Tumor Immunol 19:206-217, 1996
7. Albertini M, Hank J, Schiller J, et al: Phase 1b trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. Clin Cancer Res 3:1277-1288, 1997
8. Cheung NK, Kushner BH, Yeh SD, et al: 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: A phase II study. Int J Oncol 12:1299-1306, 1998
9. Cheung NV, Lazarus H, Miraldi FD, et al: Reassessment of patient response to monoclonal antibody 3F8. J Clin Oncol 10:671-672, 1992
10. Houghton AN, Lloyd KO: Stuck in the MUC on the long and winding road. Nat Med 4:270-271, 1998
11. Weber LW, Bowne WB, Wolchok JD, et al: Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest 102:1258-1264, 1998
12. Wolpoe ME, Lutz ER, Ercolini AM, et al: HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neutransgenic mice. J Immunol 171:2161-2169, 2003
13. Clynes RA, Towers TL, Presta LG, et al: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443-446, 2000
14. Uchida J, Hamaguchi Y, Oliver JA, et al: The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 199: 1659-1669, 2004
15. Weng WK, Levy R: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940-3947, 2003
16. Cartron G, Dacheux L, Salles G, et al: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754-758, 2002
17. Dudley ME, Wunderlich JR, Bobbins PF, et al: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-854, 2002